Comparative Pharmacology
Head-to-head clinical analysis: ELFABRIO versus LUMIZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELFABRIO versus LUMIZYME.
ELFABRIO vs LUMIZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA), which hydrolyzes lysosomal glycogen. It provides exogenous enzyme to reduce accumulation of glycogen in lysosomes.
1 mg/kg intravenously over 2 hours every 2 weeks.
5 mg/kg administered intravenously once every 2 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
Terminal half-life: 1.1–3.5 hours (mean 2.2 hours) after IV infusion; due to rapid uptake into lysosomes, shorter than many enzymes.
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
Eliminated via reticuloendothelial system; no significant renal or biliary excretion. <5% recovered unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy